<DOC>
	<DOCNO>NCT01538446</DOCNO>
	<brief_summary>The purpose study demonstrate superiority strategy platelet monitoring ( Monitoring Arm ) down-adjustment dose prasugrel high responder up-adjustment dose prasugrel low responder compare conventional strategy fix dose 5 mg every patient without monitoring ( Conventional Arm ) measure reduction composite endpoint , cardiovascular ( CV ) death , myocardial infarction ( MI ) , stroke , stent thrombosis ( ARC definition type `` definite '' ) , urgent revascularisation bleeding ( BARC definition type 2 , 3 5 ) .</brief_summary>
	<brief_title>Tailored Antiplatelet Therapy Versus Recommended Dose Prasugrel</brief_title>
	<detailed_description>Objective : To demonstrate superiority strategy platelet monitoring ( Monitoring Arm ) down-adjustment dose prasugrel high responder up-adjustment dose prasugrel low responder compare conventional strategy fix dose 5 mg every patient without monitoring ( Conventional Arm ) .Rationale : Prasugrel 10 mg superior clopidogrel patient acute coronary syndrome treat percutaneous coronary intervention , reduce significantly rate ischemic event . Elderly patient appear high risk bleed event pharmacokinetic data suggests elderly patient expose high concentration active metabolite prasugrel . A reduced dose 5 mg prasugrel therefore propose patient limit risk bleed . On hand , elderly also high ischemic risk high level platelet aggregation treatment young patient may deserve strong protection antiplatelet therapy . Platelet function test appear particular interest patient high risk ischemic bleed event like elderly . Too intense platelet inhibition may expose elderly patient excessive bleeding risk . Too low platelet inhibition may expose recurrent cardiovascular ischemic event . The possibility bedside monitor oral antiplatelet therapy offer opportunity tailor prasugrel therapy elderly patient optimize risk/benefit ratio . Such strategy never evaluate randomize adequately power study . Population : Acute coronary syndrome ( STEMI NSTEMI ) treat PCI-stent ( bare metal stent drug elute stent ) patient age 75 ≥ year . Methods : Monitoring VerifyNow P2Y12 , 2 week initiation 5 mg maintenance dose prasugrel , reduction antiplatelet therapy high on-treatment platelet inhibition ( HPI ) increase dose high on-treatment platelet reactivity ( HPR ) . Patients monitor 2 week later , meet Verifynow P2Y12 target first assessment . Primary endpoint net clinical benefit 12 month : Composite Cardiovascular death , myocardial infarction , stroke , urgent revascularisation , stent thrombosis bleeding accord BARC definition ( type 2 , 3 5 ) Centers : Approximately 40 French high volume PCI center</detailed_description>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<criteria>Acute coronary syndrome ( STEMI NSTEMI ) treat PCI Stent ( bare metal stent drug elute stent ) regardless regime thienopyridines administer randomisation Age ≥ 75 year . Aspirin dose 75 mg recommend study authorizes dose range 75160 mg Ability understand comply study protocol . Written inform consent Prior history ischemic hemorrhagic stroke transient ischemic attack , subarachnoids haemorrhage Have receive fibrinolytic therapy within 48 hour entry randomisation study Are receive vitamin K antagonist Concomitant medical illness ( terminal malignancy ) associate reduced survival expect study treatment period . History intolerance allergy ASA approve thienopyridines ( ticlopidine , clopidogrel , prasugrel ) Have active pathological bleeding history bleed diathesis Thrombocytopenia &lt; 100 000 µL Severe hepatic impairment ( Child Pugh class C ) . Have condition associate poor treatment compliance , include dementia mental illness</criteria>
	<gender>All</gender>
	<minimum_age>75 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Elderly</keyword>
	<keyword>Acute coronary syndrome</keyword>
	<keyword>Percutaneous coronary intervention</keyword>
	<keyword>Prasugrel</keyword>
	<keyword>Platelet function test</keyword>
</DOC>